Brendan Coffman is a partner in the Washington, D.C., office of Wilson Sonsini Goodrich & Rosati, where he is a member of the antitrust and competition practice. Brendan represents the world's most innovative companies in connection with mergers and acquisitions, joint ventures, government investigations, private litigation, and distribution practices. His clients include stalwarts and emerging firms in electronic gaming and entertainment, ridesharing and ADAS/Autonomous Driving, semiconductor and connectivity, pharmaceutical, healthcare, and financial services. Representative matters include the following:

Mergers:

• Hawaiian Airlines in its $1.9 billion acquisition by Alaska Airlines, the first airline merger cleared by the antitrust agencies in nearly a decade
• Recursion Pharmaceuticals in its $700 million acquisition of Exscientia
• Silk Road in its $1.16 billion acquisition by Boston Scientific
• Vizio in its $2.3 billion acquisition by Walmart
• Dren Bio in its strategic collaboration with Novartis
• Bungie in its $3.6 billion acquisition by Sony
• DTx Pharma in its acquisition by Novartis, valued up to $1 billion
• Qualcomm in its acquisitions of Veoneer, Skyhook, and Cellwize
• Element Biosciences as a third party in the FTC’s challenge of Illumina/Grail
• Lyft in its $500 million sale of L5 Assets to Toyota’s Woven Planet
• Plaid in its $5.3 billion acquisition by Visa
• Careem in its $3.1 billion acquisition by Uber
• Lumentum in its $1.8 billion acquisition of Oclaro
• NetSuite in its $9.3 billion acquisition by Oracle
• Trulia in its $3.5 billion acquisition by Zillow
• Fiserv, Inc. in its $700 million acquisition of Elan Financial Services
• Google in its acquisitions of Waze and Nest

Antitrust Litigation:

• Mylan Pharmaceuticals in several matters pertaining to insulin glargine, including as lead counsel in affirmative litigation against Sanofi alleging illegal monopolization of the insulin glargine market
• Open To The Public Investing, Inc. (“Public.com”) in In re January 2021 Short Squeeze Trading Litigation; obtained voluntary dismissal
• Mylan Pharmaceuticals as plaintiff against Teva Corporation alleging monopolization of the market for multiple sclerosis treatment Copaxone
• Reddy’s Laboratories in monopolization case against Amarin pertaining to Vascepa
• Mylan Pharmaceuticals as plaintiff against Celgene Corporation alleging monopolization of the markets for cancer Thalomid and Revlimid; prevailed at summary judgment and obtained favorable monetary settlement
• Mylan Pharmaceuticals in In re Generic Pharmaceuticals Pricing Antitrust Litigation
• Lupin Pharmaceuticals in In re Glumetza Antitrust Litigation
• BlueCross BlueShield of Tennessee as a non-party in Anthem Inc. v. Cigna Corp.

Government Investigations:

• Represented cooperating witness in U.S. v. Usher et al., the Department of Justice’s investigation and criminal prosecution in the foreign exchange market
• Represented four other traders across three financial instruments in connection with government investigations in the United States and internationally

Antitrust Counseling:

• Represent many leading technology companies in connection with regulatory investigations touching upon all areas of antitrust jurisprudence
• Range of intellectual property issues, including standard-essential patents, participation in standard-development organizations, patent pooling, and other competition risks associated with patent assertion and aggregation
• Pricing practices including price discrimination, most favored nation clauses (MFNs), minimum requirements, exclusivity, and conditional payment terms